Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

del(X)(p22p22) CSF2RA/CRLF2

Written2018-01Jean-Loup Huret, Philippe Dessen

(Note : for Links provided by Atlas : click)

Identity

ICD-Topo C420,C421,C424 BLOOD, BONE MARROW, & HEMATOPOIETIC SYS
Atlas_Id 2120
Note Non-annotated chromosomal abnormality. Preliminary data :
if you are an author who wish to write a full paper/card on this translocation, go to  How to contribute

Clinics and Pathology

Disease Acute lymphoblastic leukemia/lymphoblastic lymphoma

Genes involved and Proteins

Gene NameCSF2RA
Location Xp22.32 and Yp11.3
Gene NameCRLF2
Location Xp22.3 and Yp11.3

Bibliography

An overall characterization of pediatric acute lymphoblastic leukemia with CRLF2 overexpression
Yano M, Imamura T, Asai D, Moriya-Saito A, Suenobu S, Hasegawa D, Deguchi T, Hashii Y, Kawasaki H, Hori H, Kosaka Y, Kato K, Horibe K, Yumura-Yagi K, Hara J, Matsumoto K, Kiyokawa N, Oda M, Sato A; Japan Association of Childhood Leukemia Study
Genes Chromosomes Cancer 2014 Oct;53(10):815-23
PMID 24935070
 


Other genes implicated (Data extracted from papers in the Atlas) [ 1 ]

Genes NFKB2

Translocations implicated (Data extracted from papers in the Atlas)

 del(X)(p22p22) CSF2RA/CRLF2

External links

CSF2RA (Xp22.32 and Yp11.3)

Mitelman databasedel(X)(p22p22) [Case List]    del(X)(p22p22) [Transloc-MCList] CSF2RA/CRLF2 [Fusion-MCList]
COSMICHisto = - Site = haematopoietic_and_lymphoid_tissue (COSMIC)
arrayMap (UZH-SIB Zurich)[select an item]
 
 
REVIEW articlesautomatic search in PubMed
Last year articlesautomatic search in PubMed
All articlesautomatic search in PubMed


© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Mon Jul 9 10:12:47 CEST 2018


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.